Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Allison

Showing results (611-620 of 647) with videos related to

Pageof 65
Sort By:
Cancer Immunology Research|October 30, 2019
Phase II Trial of Ipilimumab with Stereotactic Radiation Therapy for Metastatic Disease: Outcomes, Toxicities, and Low-Dose Radiation-Related Abscopal ResponsesJames W Welsh, Chad Tang, Patricia de Groot, et al.
Nature Communications|October 19, 2021
Single cell T cell landscape and T cell receptor repertoire profiling of AML in context of PD-1 blockade therapyHussein A Abbas, Dapeng Hao, Katarzyna Tomczak, et al.
Oncoimmunology|May 4, 2016
Distinct clinical patterns and immune infiltrates are observed at time of progression on targeted therapy versus immune checkpoint blockade for melanomaZachary A Cooper, Alexandre Reuben, Christine N Spencer, et al.
Cancer Cell|May 10, 2022
Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunityYared Hailemichael, Daniel H Johnson, Noha Abdel-Wahab, et al.
Cancer Discovery|July 23, 2017
TCR Repertoire Intratumor Heterogeneity in Localized Lung Adenocarcinomas: An Association with Predicted Neoantigen Heterogeneity and Postsurgical RecurrenceAlexandre Reuben, Rachel Gittelman, Jianjun Gao, et al.
Cancer Discovery|June 13, 2015
Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilitiesFerdinandos Skoulidis, Lauren A Byers, Lixia Diao, et al.
Research Square|July 28, 2023
Inflammation induced by tumor-associated nerves promotes resistance to anti-PD-1 therapy in cancer patients and is targetable by interleukin-6 blockadeErez N Baruch, Priyadahrshini Nagarajan, Frederico O Gleber-Netto, et al.
Nature Communications|April 17, 2020
Spatially resolved analyses link genomic and immune diversity and reveal unfavorable neutrophil activation in melanomaAkash Mitra, Miles C Andrews, Whijae Roh, et al.
Physical Review Letters|January 15, 2011
Observation of ultrahigh-energy cosmic rays with the ANITA balloon-borne radio interferometerS Hoover, J Nam, P W Gorham, et al.
Nature|March 9, 2023
Author Correction: Neoadjuvant relatlimab and nivolumab in resectable melanomaRodabe N Amaria, Michael Postow, Elizabeth M Burton, et al.
Pageof 65

Showing results (611-620 of 647) with videos related to

Sort By:
Pageof 65
Cancer Immunology Research|October 30, 2019
Phase II Trial of Ipilimumab with Stereotactic Radiation Therapy for Metastatic Disease: Outcomes, Toxicities, and Low-Dose Radiation-Related Abscopal ResponsesJames W Welsh, Chad Tang, Patricia de Groot, et al.
Nature Communications|October 19, 2021
Single cell T cell landscape and T cell receptor repertoire profiling of AML in context of PD-1 blockade therapyHussein A Abbas, Dapeng Hao, Katarzyna Tomczak, et al.
Oncoimmunology|May 4, 2016
Distinct clinical patterns and immune infiltrates are observed at time of progression on targeted therapy versus immune checkpoint blockade for melanomaZachary A Cooper, Alexandre Reuben, Christine N Spencer, et al.
Cancer Cell|May 10, 2022
Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunityYared Hailemichael, Daniel H Johnson, Noha Abdel-Wahab, et al.
Cancer Discovery|July 23, 2017
TCR Repertoire Intratumor Heterogeneity in Localized Lung Adenocarcinomas: An Association with Predicted Neoantigen Heterogeneity and Postsurgical RecurrenceAlexandre Reuben, Rachel Gittelman, Jianjun Gao, et al.
Cancer Discovery|June 13, 2015
Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilitiesFerdinandos Skoulidis, Lauren A Byers, Lixia Diao, et al.
Research Square|July 28, 2023
Inflammation induced by tumor-associated nerves promotes resistance to anti-PD-1 therapy in cancer patients and is targetable by interleukin-6 blockadeErez N Baruch, Priyadahrshini Nagarajan, Frederico O Gleber-Netto, et al.
Nature Communications|April 17, 2020
Spatially resolved analyses link genomic and immune diversity and reveal unfavorable neutrophil activation in melanomaAkash Mitra, Miles C Andrews, Whijae Roh, et al.
Physical Review Letters|January 15, 2011
Observation of ultrahigh-energy cosmic rays with the ANITA balloon-borne radio interferometerS Hoover, J Nam, P W Gorham, et al.
Nature|March 9, 2023
Author Correction: Neoadjuvant relatlimab and nivolumab in resectable melanomaRodabe N Amaria, Michael Postow, Elizabeth M Burton, et al.
Pageof 65